
Palisade Bio, Inc. Share Price
PALI$0.64
+$0.01 (2.35%) Last updated on 06 Sep, 2025 | 01:28 ISTPalisade Bio, Inc. Stock Performance
Open $0.63 | Prev. Close $0.62 | Circuit Range N/A |
Day Range $0.60 - $0.66 | Year Range $0.60 - $4.32 | Volume 1,45,640 |
Average Traded $0.63 |
Palisade Bio, Inc. Share Price Chart
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Palisade Bio, Inc. Historical Data
Day | Open | Close | Change % |
---|---|---|---|
05-Sep-25 | $0.63 | $0.64 | +2.40% |
04-Sep-25 | $0.64 | $0.62 | -3.11% |
03-Sep-25 | $0.65 | $0.64 | -1.08% |
02-Sep-25 | $0.66 | $0.65 | -3.41% |
29-Aug-25 | $0.67 | $0.67 | +0.15% |
28-Aug-25 | $0.66 | $0.67 | -0.15% |
27-Aug-25 | $0.68 | $0.67 | -1.03% |